



(11) Publication number: **0 583 665 A2**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: **93112181.8**

(22) Date of filing: **29.07.93**

(51) Int. Cl.⁵: **A61K 31/05, A61K 31/165,
A61K 31/215, A61K 31/235,
A61K 31/415, A61K 31/505,
A61K 31/535**

(30) Priority: **30.07.92 JP 204122/92
02.09.92 JP 234767/92**

(43) Date of publication of application:
23.02.94 Bulletin 94/08

(84) Designated Contracting States:
CH DE FR GB IT LI

(71) Applicant: **FUJI PHOTO FILM CO., LTD.
No. 210, Nakanuma
Minami-Ashigara-shi
Kanagawa-ken(JP)**

(72) Inventor: **Aikawa, Kazuhiro, c/o Fuji Photo
Film Co., Ltd.
No. 210, Nakanuma
Minami-Ashigara-shi, Kanagawa-ken(JP)**
Inventor: **Aoki, Kozo, c/o Fuji Photo Film Co.,
Ltd.
No. 210, Nakanuma
Minami-Ashigara-shi, Kanagawa-ken(JP)**

(74) Representative: **Hansen, Bernd, Dr.
Dipl.-Chem. et al
Hoffmann, Eitle & Partner,
Patentanwälte,
Arabellastrasse 4
D-81925 München (DE)**

(54) **Pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis.**

(57) Disclosed are an antihyperlipidemia or antiarteriosclerosis agent comprising a certain benzimidazole or 2,2'-methylenebisphenol derivative such as 5-dodecanoylamino-2-mercaptobenzimidazole or 2,2'-isobutylidenebis-(4,6-dimethylphenol).

EP 0 583 665 A2

Background of the Invention

The present invention relates to a novel pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis, more specifically to an antihyperlipidemia agent having a blood cholesterol lowering effect or an antiarteriosclerosis agent having a macrophage-foaming reaction suppressing effect and a method for treating hyperlipidemia and arteriosclerosis using this composition.

As people have become more affluent, their eating habits have changed toward increased intake of foods with high cholesterol content and high caloric value. As a result, hyperlipidemia and arteriosclerosis are increasing rapidly in conjunction with the aging of the population. This has become a major social problem.

Hitherto, drug therapy for hyperlipidemia and arteriosclerosis has been directed only to lowering blood cholesterol. No drug capable of reversing the effects of arteriosclerosis is available.

Arteriosclerosis is characterized by thickening of the blood vessel intima and lipid deposition within the blood vessel. Therefore, for drug therapy of the disease, drugs capable of lowering blood cholesterol have been used. However, it has been found that the macrophage-foaming reaction plays an important role in forming the focus of arteriosclerosis. Thus, it is expected that suppression of this reaction would result in regression of the arteriosclerosis foci.

Summary of the Invention


A primary object of the present invention is to provide a novel and low toxic pharmaceutical composition capable of lowering blood cholesterol and suppressing macrophage-foaming reaction by way of inhibiting acyl-CoA cholesterolacyltransferase (ACAT) activity and intracellular cholesterol transport.




Another object of the present invention is to provide a method for treating hyperlipidemia and arteriosclerosis.

These and other objects of the present invention will be apparent from the following description and Examples.

The above objects were achieved based on the discovery that certain benzimidazole and 2,2'-methylenebisphenol derivatives have not only an ACAT activity-inhibiting effect, an intracellular cholesterol transport-inhibiting effect and an excellent blood cholesterol lowering effect but also a macrophage-foaming reaction suppressing effect, and, as such, are able to achieve the aforesaid object.

The first aspect of the present invention relates to a pharmaceutical composition comprising a compound of the following formula (I), (II) or (III), or a pharmaceutically-acceptable salt thereof, or a compound of the following formula (IV) as an active ingredient together with a pharmaceutical-acceptable carrier or diluent:





wherein

35 R_1 represents a hydrogen atom, an alkyl, an aryl, a mercapto, an alkylthio, an alkenylthio, an arylthio or a heterocyclo group;

R_2 represents a hydrogen atom or an alkyl group, provided that the alkyl group is not substituted by a hydroxyl group;

40 R_3 and R_4 each independently represents a hydrogen atom, a halogen atom, a nitro group, R_5O- , R_5CONH- , R_5NHCO- , $(R_5)_2NCO-$, R_5SO_2NH- , R_5NHSO_2- , R_5OCO- , R_5COO- or $R_5NHCONH-$ where R_5 represents an alkyl or an aryl group;

R_6 represents a divalent group;

45 R_7 , R_8 , R_9 and R_{10} each independently represents an alkyl, a cycloalkyl group, $-(C(CH_3)_2)_k-(CH_2)_mCOOR_{14}$ or $-(C(CH_3)_2)_k-(CH_2)_mCON(R_{14})_2$ where k represents 0 or 1, m represents an integer of 0 to 4 and R_{14} represents a lower alkyl group;

R_{11} and R_{12} each independently represents a hydrogen atom, an alkyl, an aryl or an aralkyl group; and


R_{13} represents a hydrogen atom, a lower alkyl, an aralkyl, an acyl, an alkyl- or arylsulfonyl group, or $-(CH_2)_nCOOR_{15}$ where n represents an integer of 0 to 2 and R_{15} represents a lower alkyl group.

50 The second aspect of the present invention relates to a use of a compound of the formula (I), (II) or (III), or a pharmaceutically-acceptable salt thereof, or a compound of the formula (IV) for preparing an antihyperlipidemia or antiarteriosclerosis agent.

Detailed explanation of preferred Embodiments

55 The present invention provides a pharmaceutical composition which has an excellent blood cholesterol lowering effect and macrophage-foaming reaction suppressing effect and is low in toxicity, it therefore exhibits an excellent therapeutic effect on hyperlipidemia and arteriosclerosis and is administrable over a long period.

Among the compounds of the formulae (I), (II), (III) and (IV), the compounds of the formulae (I) and (IV) are preferable and, in the compounds of the formula (I), the compounds of the following formula (V) are particularly preferable;



wherein

- 15 R_1 represents a hydrogen atom, an alkyl, a mercapto or an alkylthio group; and
 R_3 represents a hydrogen atom, a halogen atom, a nitro group, R_5O- , R_5CONH- , R_5NHCO- , R_5NHSO_2- or R_5SO_2NH- where R_5 represents an alkyl group.

The compounds of the formulae (I), (II), (III) and (V) of the present invention will now be described in detail.

- 20 Examples of the alkyl groups represented by R_1 in the formulae (I), (III) and (V) include alkyl groups having 1 to 18 carbon atoms (such as methyl, ethyl, butyl, octyl, dodecyl and octadecyl groups). Alkyl groups having 1 to 8 carbon atoms (such as methyl, ethyl, butyl and octyl groups), which may be straight or branched chains, are preferable. Examples of the aryl groups include phenyl and naphthyl groups. Phenyl group is particularly preferable. Examples of the alkyl groups of the alkylthio groups include alkyl groups
 25 having 1 to 18 carbon atoms (such as methyl, ethyl, butyl, octyl, dodecyl and octadecyl groups). Alkyl groups having 1 to 8 carbon atoms (such as methyl, ethyl, butyl and octyl groups), which may be straight or branched chains, are preferable. Examples of the alkenyl groups of the alkenylthio groups include alkenyl groups having 2 to 18 carbon atoms (such as allyl and octadecenyl groups). Examples of the aryl groups of the arylthio groups include phenyl and naphthyl groups. Phenyl group is particularly preferable. Examples
 30 of the heterocyclo groups of the heterocyclothio groups include pyridyl and hexahydropyridyl groups. 2- and 4-pyridyl groups are particularly preferable.

Each of the alkyl, aryl, alkylthio, alkenylthio, arylthio and heterocyclothio groups represented by R_1 may be optionally substituted. Examples of the substituents include halogen atoms, alkyl, aryl, alkoxy, aryloxy, acylamino and nitro groups.

- 35 Preferred groups represented by R_1 are hydrogen atom, alkyl groups, mercapto group and alkylthio groups. Specific examples of the preferred groups represented by R_1 include methyl, butyl, mercapto and methylthio groups.

- Next, examples of the alkyl groups represented by R_2 in the formulae (I) to (III) include alkyl groups having 1 to 12 carbon atoms (such as methyl, butyl, hexyl, octyl and dodecyl groups). Alkyl groups having
 40 1 to 6 carbon atoms (such as methyl, butyl and hexyl groups), which may be straight or branched chains, are preferable.

The alkyl group represented by R_2 may be optionally substituted. Examples of the substituents include aryl, amino and acylamino groups. The alkyl group is not substituted by hydroxy group.

- Preferred groups represented by R_2 are hydrogen atom and the alkyl groups having 1 to 6 carbon atoms, particularly hydrogen atom.

- When R_3 in the formulae (I), (II) and (V) and R_4 in the formula (I) contain R_5 , examples of the alkyl groups represented by R_5 include alkyl groups having 1 to 20 carbon atoms (such as methyl, butyl, octyl, dodecyl and octadecyl groups). Alkyl groups having 4 to 18 carbon atoms (such as methyl, butyl, octyl, dodecyl and octadecyl groups), which may be straight or branched chains, are preferable. Examples of the
 50 aryl groups include phenyl and naphthyl groups. Phenyl group is particularly preferable.

The alkyl and aryl groups represented by R_5 may be optionally substituted. Examples of the substituents include halogen atoms, alkyl, aryl, acylamino and aryloxy groups.

- Preferred groups represented by R_3 and R_4 are the above-described groups containing R_5 , that is, R_5O- , R_5CONH- , R_5NHCO- , R_5SO_2NH- , R_5NHSO_2- , R_5OCO- , R_5COO- and $R_5NHCONH-$, particularly R_5O- ,
 55 R_5CONH- , R_5NHCO- , R_5NHSO_2- and R_5SO_2NH- . Specific examples of the preferred groups include octyloxy, hexadecyloxy, dodecanoyloxy, dodecylcarbamoyl, octylsulfonylamino, dodecylsulfamoyl groups.

Examples of the divalent groups represented by R_6 in the formulae (II) and (III) include $-(CH_2)_n-$, $-O-(CH_2)_nO-$, $-NHCO(CH_2)_nCONH-$, $-NHSO_2(CH_2)_nSO_2NH-$ where n represents an integer of 1 to 10.

$-(CH_2)_n-$ and $-NHCO(CH_2)_nCONH-$ where n is 2 to 8 are particularly preferable.


Among the above-described compounds having R_1 to R_6 , preferred are the compounds in which at least one substituents have not less than 4 carbon atoms, particularly those in which at least one substituents except for R_2 have 4 to 20 carbon atoms, preferably 8 to 18 carbon atoms.

6 Examples of the pharmaceutically-acceptable salts of the compounds represented by the formulae (I), (II) and (III) include hydrochloride, hydrobromide, nitrate, sulfate and toluenesulfonate. Hydrochloride is particularly preferable.

Examples of the compounds of the formulae (I), (II) and (III) or the formula (V) of the present invention are listed below.

10


15



(1)

20


25



(2)

30

35




(3)

40




45


50




(4)

55









(8)




(9)




(10)







(14)




(15)




(16)




(17)




(18)







(19)











(20)




(21)












(34)







(35)






(36)




(37)






50


55




(45)




(46)




(47)




(48)



(49)



(50)



(51)

Next, the detailed description will be made on the compounds of the formula (IV) of the present invention.

The alkyl groups represented by R_7 to R_{10} in the formula (IV) include alkyl groups having 1 to 12 carbon atoms which may be straight or branched chains. Examples of the alkyl groups include methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, tert-pentyl, hexyl, octyl, decyl and dodecyl groups. Among these, alkyl groups having 1 to 8 carbon atoms are preferred and those having 1 to 4 carbon atoms are particularly preferred. However, alkyl groups having not less than 4 carbon atoms are also preferred insofar as they are tertiary alkyl groups (such as tert-butyl, tert-pentyl, tert-hexyl, tert-octyl groups and the

like). These alkyl groups may be optionally substituted. Examples of the substituents include halogen atoms such as chlorine, bromine, fluorine and iodine.

The cycloalkyl groups represented by R_7 to R_{10} include cyclopentyl, cyclohexyl and cycloheptyl groups. These cycloalkyl groups may be optionally substituted. Examples of the substituents include lower alkyl groups such as methyl and ethyl groups and halogen atoms such as chlorine, bromine, fluorine and iodine. Cycloalkyl groups substituted by methyl group are preferred.

When R_7 to R_{10} represent $-(C(CH_3)_2)_k-(CH_2)_mCOOR_{14}$ or $-(C(CH_3)_2)_k-(CH_2)_mCON(R_{14})_2$, the lower alkyl groups represented by R_{14} include alkyl groups having 1 to 4 carbon atoms which may be straight or branched chains. Examples of the alkyl groups include methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl and tert-butyl groups, preferably methyl and ethyl groups. k is preferably 1 and m is preferably 3.

Preferable groups represented by R_7 to R_{10} are alkyl groups having 1 to 4 carbon atoms and cycloalkyl groups substituted by methyl group, particularly methyl and tert-butyl groups.

The alkyl groups represented by R_{11} and R_{12} in the formula (IV) include alkyl groups having 1 to 13 carbon atoms which may be straight or branched chains. Examples of the alkyl groups include methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, hexyl, octyl, decyl and dodecyl groups. Among these, alkyl groups having 1 to 8 carbon atoms are preferred and those having 1 to 4 carbon atoms are particularly preferred.

The aryl groups represented by R_{11} and R_{12} include phenyl, tolyl, xylyl and naphthyl groups. Phenyl group is preferable.

The aralkyl groups represented by R_{11} and R_{12} include benzyl and phenethyl groups.

In the preferable combination of R_{11} and R_{12} , one is a hydrogen atom and the other is a lower alkyl group having 1 to 4 carbon atoms.

The lower alkyl groups represented by R_{13} in the formula (IV) include alkyl groups having 1 to 4 carbon atoms which may be straight or branched chains. Examples of the alkyl groups include methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl and tert-butyl groups. Methyl and ethyl groups are preferable.

The aralkyl groups represented by R_{13} include benzyl and phenethyl groups.

The acyl groups represented by R_{13} include aliphatic and aromatic acyl groups. Examples of the aliphatic acyl groups include acyl groups having 2 to 6 carbon atoms (such as acetyl, propionyl, pentanoyl and the like), which may be straight or branched chains. Examples of the aromatic acyl groups include benzoyl group. These acyl groups may be optionally substituted. Examples of the substituents of the aliphatic acyl groups include lower alkoxy groups and phenoxy group. These substituents may further be substituted by one or more substituents including lower alkyl groups such as methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl and tert-butyl groups and halogen atoms such as chlorine, bromine, fluorine and iodine. Examples of the substituents of the aromatic acyl groups include lower alkyl groups such as methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl and tert-butyl groups and halogen atoms such as chlorine, bromine, fluorine and iodine.


Examples of the alkylsulfonyl groups represented by R_{13} include alkylsulfonyl groups having 2 to 4 carbon atoms (such as methanesulfonyl, ethanesulfonyl, propanesulfonyl and the like), which may be straight or branched chains. Examples of the arylsulfonyl groups represented by R_{13} include benzenesulfonyl and p-toluenesulfonyl groups.

When R_{13} represents $-(CH_2)_nCOOR_{15}$, the lower alkyl groups represented by R_{15} include alkyl groups having 1 to 4 carbon atoms which may be straight or branched chains. Examples of the alkyl groups include methyl, ethyl, n-propyl, isopropyl, isobutyl, sec-butyl and tert-butyl groups. Methyl and ethyl groups are preferable. n is preferably 0 or 1.


R_{13} is preferably a hydrogen atom.

Examples of the compounds of the general formula (IV) of the present invention are listed below.


(52)




(53)




(54)




(55)




(56)




(57)




(58)




(59)




(60)




(61)






(62)




(63)







(67)




(68)




(69)




(70)




(71)




(72)




(73)




(74)



(75)



(76)



The method for preparing these compounds will now be described in detail.

Benzimidazole ring which is basic skeleton of the compounds of the formulae (I), (II) and (III) is generally synthesized using a o-phenylenediamine as a starting material. That is 2-mercaptobenzimidazoles are generally synthesized by reacting o-phenylenediamines with carbon disulfide under a basic condition and 2-alkyl- or 2-aryl benzimidazoles are generally synthesized by reacting o-phenylenediamines with carboxylate or orthocarboxylate under an acidic condition.

On the other hand, 2,2'-methylenebisphenol derivatives of the compounds of the formula (IV) are generally synthesized by subjecting a phenol and an aldehyde or ketone to dehydrocondensation under an acidic condition. However, it is possible to obtain the compounds by subjecting a phenol derivative and an aldehyde or ketone to equimolar addition reaction under a basic condition to obtain a methylol intermediate and then reacting this intermediate with the equimolar phenol under an acidic condition. The latter method is particularly useful for preparing an unsymmetrical 2,2'-methylenebisphenol derivative.

Synthesis Example 1 Synthesis of 2-methyl-5-nitrobenzimidazole (5)

15.3 g of 3,4-dinitrobenzene was added to 64 ml of acetic anhydride and 2 ml of conc. hydrochloric acid and the mixture was refluxed for 3 hours. After cooling, the formed crystals were dispersed in 10 % sodium hydroxide aqueous solution and then filtered off. The crystals were recrystallized from water-containing ethanol to obtain 6 g of compound (5).

Melting point : 220-221 °C

Elemental analysis (%):		Anal.	C 54.42	H 4.03	N 23.62
		Cal.	C 54.23	H 3.98	N 23.72

Synthesis Example 2 Synthesis of 1,8-bis(5-nitrobenzimidazol-2-yl) octane (6)

10.8 g of o-phenylenediamine and 10.1 g of sebacic acid were added to 120 ml of 4 N hydrochloric acid and the mixture was refluxed for 6 hours. After cooling, the formed crystals were filtered off and washed with 1 N sodium carbonate aqueous solution until the washing solution maintained an alkalinity. After separating and drying the crystals, they were dissolved in 35 ml of conc. sulfuric acid and 3.8 g of potassium nitrate was added thereto little by little while stirring under cooling with ice. After stirring for 2 hours under cooling with ice, the solution was poured into ice-water and the formed crystals were washed with 1 N sodium carbonate aqueous solution until the washing solution maintained an alkalinity. The crystals were recrystallized from water-containing ethanol to obtain 3.4 g of compound (6).

Melting point : 135-137 °C

EP 0 583 665 A2

Elemental analysis (%):	Anal.	C 60.62	H 19.25	N 5.41
	Cal.	C 60.54	H 19.26	N 5.54

6

Synthesis Example 3 Synthesis of 2-mercapto-5-methoxybenzimidazole(13)

70 ml of ethanol and 15 ml of carbon disulfide were added to 2.6 g of 3,4-diaminoanisole and then a solution of 1.5 g of sodium hydroxide in 5 ml of water was added thereto. After heating with a water bath for 3.5 hours, the mixture was cooled with ice, filtered and then the solvent in the filtrate was distilled off under reduced pressure. The residue was dissolved in ethanol. The solution was filtrated to remove the insoluble matter and then the solvent in the filtrate was distilled off under reduced pressure. The residue was recrystallized from water-containing methanol to obtain 2.0 g of the titled compound (13).
Melting point : 254-255 °C

15

Elemental analysis (%):	Anal.	C 53.06	H 4.52	N 15.27
	Cal.	C 53.33	H 4.44	N 15.56

20

Synthesis Example 4 Synthesis of 2-benzylthiobenzimidazole (7)

15 g of 2-mercaptobenzimidazole and 16.5 g of benzylbromide were dissolved in 50 ml of ethanol and the mixture was refluxed with a water bath for 5 hours. After cooling, the formed crystals were collected and recrystallized from ethanol to obtain 18 g of compound (7).
Melting point : 185-186 °C

30

Elemental analysis (%):	Anal.	C 69.59	H 5.30	N 11.74
	Cal.	C 69.99	H 5.03	N 11.66

Synthesis Example 5 Synthesis of 5-dodecanoylamino-2-mercaptobenzimidazole (8)

5 g of 5-amino-2-mercaptobenzimidazole was dissolved in 50 ml of pyridine and 7.95 g of dodecanoyl chloride was added dropwise thereto under cooling with ice. After stirring for 3 hours at room temperature, the solution was poured into ice-water. The formed crystals were filtered off and recrystallized from water-containing methanol to obtain 10.9 g of compound (8).
Melting point : 266-267 °C

40

Elemental analysis (%):	Anal.	C 66.38	H 8.54	N 11.34
	Cal.	C 65.71	H 8.36	N 12.10

45

Synthesis Example 6 Synthesis of 2-morpholinomethylbenzimidazole (36)

To 108 g of o-phenylenediamine, 1 l of 4 N hydrochloric acid and 142 g of chloroacetic acid were added and refluxed for 1.5 hours. After allowing to stand overnight, the solution was diluted with 2 l of water and neutralized with dilute ammonia water. The formed crystals were filtered off to obtain 113 g of 2-chloromethylbenzimidazole.

10 g of 2-chloromethylbenzimidazole thus obtained and 10.5 g of morpholine were dissolved in 75 ml of alcohol and the solution was refluxed for 3 hours. After cooling, ether was added to the solution and the precipitated crystals were filtered off. The filtrate was washed with water and satulated with hydrogen chloride to form an oily matter. The oily matter was crystallized by adding a smoll amount of alcohol and the crystals were filtered off. The crystals were recrystallized from alcohol to obtain 2.5 g of compound (36).
Melting point : 235-236 °C

Elemental analysis (%):	Anal.	C 49.48	H 5.88	N 14.27
	Cal.	C 49.66	H 5.91	N 14.48

5

Synthesis Example 7 Synthesis of 2,2'-isobutylidenebis(4,6-dimethylphenol) (53)

36 g of isobutylaldehyde and 122 g of 2,4-dimethylphenol were mixed and 77 g of anhydrous calcium chloride was added to this mixture. The resulting mixture was heated to 60 °C and 46 ml of conc. hydrochloric acid was added dropwise over 2 hours. After stirring for 6 hours, the reaction mixture was cooled and then water and methanol were added to disperse solid matter. After filtration, the solid matter was washed with water, dried and recrystallized from hexane under cooling to obtain 102 g of compound (53).

Melting point : 163-165 °C

15

Elemental analysis (%):	Anal.	C 80.67	H 8.88
	Cal.	C 80.49	H 8.78

20

Synthesis Example 8 Synthesis of 2,2'-methylenebis(6-tert-butyl-4-methylphenol) monomethyl ether (59)

34 g of 2,2'-methylenebis(6-tert-butyl-4-methylphenol) was dissolved in 50 ml of acetone and 27.6 g of anhydrous calcium chloride was added to this solution. 15 g of methyl iodide was slowly added dropwise thereto while stirring under reflux. After stirring for 6 hours, the reaction mixture was cooled and solid matter was filtered off. The filtrate was poured into ice-water and the formed crystals were filtered off. The crystals were recrystallized from water-containing methanol to obtain 28.2 g of compound (59).

Melting point : 163-165 °C

30

Elemental analysis (%):	Anal.	C 81.06	H 9.54
	Cal.	C 81.31	H 9.67

35 Synthesis Example 9 Synthesis of 2,2'-ethylidenebis(4,6-di-tert-pentylphenol) (63)

70.4 g of 2,4-di-tert-pentylphenol and 9.9 g of paraformaldehyde were dissolved in 100 ml of toluene and 5.7 g of p-toluenesulfonic acid was added thereto. The solution was heated to 70 °C and 30 ml of toluene was distilled off over 3 hours under reduced pressure of 100-135 mmHg. After cooling, water was added to the solution and the water phase was neutralized with sodium hydrogen carbonate. Then, the toluene phase was washed with water, the solvent was distilled off under reduced pressure and the residue was recrystallized from water-containing methanol to obtain 52 g of compound (63).

Melting point : 116-118 °C

45

Elemental analysis (%):	Anal.	C 82.67	H 10.92
	Cal.	C 82.53	H 11.00

The following compounds were synthesized according to the method above described. The melting points of the crystalline compounds are as follows:

55

EP 0 583 665 A2

	Compound No.	m.p.(°C)	Compound No.	m.p.(°C)
5	(1)	195-200 (HCl salt)	(2)	200-203
10	(3)	133-135 (HBr salt)	(4)	167-170
	(5)	220-221	(6)	135-137
	(7)	190-191	(8)	226-267
15	(9)	266-268	(10)	275-276
	(11)	>300	(12)	>280
	(13)	254-255	(14)	128-129
20	(15)	95-97	(16)	106-108
	(17)	181-183	(18)	119-123
25	(20)	84-87	(21)	183-186
	(23)	250-252	(24)	214-217
	(25)	200 (decomp.)	(26)	284-286
30	(27)	230-232	(28)	132-134
	(29)	217 (decomp.)	(30)	243-245
	(31)	143-144	(32)	>250
35	(33)	124-125	(34)	218-220
	(35)	215-217 (HCl salt)	(36)	235 (decomp.)
40				(HCl salt)
	(37)	162-164	(38)	215-216
	(39)	202-203	(42)	230-231
45	(43)	155-156	(44)	163-164
	(45)	146 (decomp.)	(46)	197-199
	(47)	54-56	(48)	60-63
50	(49)	82-85	(50)	188-191

55

	(51)	209-212		
5	(52)	123-124	(53)	163-165
	(54)	171-173	(55)	124-125
	(56)	117-118	(57)	105-106
10	(58)	98-101	(59)	120-123
	(60)	171-172	(61)	92-95
	(62)	128-131	(63)	116-118
15	(64)	101-102	(67)	53-56
	(68)	162-165	(74)	139-140

20

Compounds (65), (72) and (73) are oily and compounds (66), (69), (70), (71), (75) and (76) are non-crystalline. Accordingly, they have no melting point.

25 The pharmaceutical composition of the present invention may contain one or more compounds of formulae (I) to (IV) and may be used in combination with the known antihyperlipidemia and antiarteriosclerosis agents that are conventionally used and are compatible with the compounds of the present invention. Examples of known antihyperlipidemia and antiarteriosclerosis agents include Melinamide, Probucol and Mevalotin.

30 The pharmaceutical composition of the present invention may be administered, for example, orally or by injection (mainly intramuscular, intravenous or subcutaneous route) and is usually prepared in the form of a formulation suitable for the administration route. Thus, the pharmaceutical composition can be used as an oral formulation such as tablet, powder, granule, capsule, syrup, emulsion, suspension or solution, or injection. The formulations can be prepared by mixing the compound of the present invention with a pharmaceutical-acceptable carrier, diluent and/or bioactive substance.

35 Examples of pharmaceutical carriers or diluents suitable for combining with the compound of formula (I) to (IV) include glucose; saccharose; lactose; ethanol; glycerin; mannitol; sorbitol; pentaerythritol; diethylene glycol, triethylene glycol, ethylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol 400, other polyethylene glycols than polyethylene glycol 400; mono-, di- and triglycerides of saturated fatty acids such as triauryl glyceride, monostearoyl glyceride, tristearoyl glyceride and distearoyl glyceride; pectin; 40 starch; corn starch; arginic acid; xylose; talc, lycopodium; oils and fats such as olive oil, peanut oil, castor oil, corn oil, wheat malt oil, sesame oil, cottonseed oil, sunflower oil and cod-liver oil; gelatin; lecithin; silica; cellulose; cellulose derivatives such as hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose and calcium carboxymethyl cellulose; magnesium or calcium salts of fatty acids having 12 to 22 carbon atoms such as calcium stearate, calcium laurate, magnesium oleate, calcium palmitate, calcium 45 behenate and magnesium stearate; cyclodextrins such as α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, dihydroxypropyl- β -cyclodextrin, carboxymethyl ethyl- β -cyclodextrin and dimethyl- β -cyclodextrin; emulsifiers such as esters of saturated and unsaturated fatty acids having 2 to 22, particularly 10 to 18 carbon atoms, with monovalent aliphatic alcohols (for example, alkanols having 1 to 20 carbon atoms such as glycol, glycerin, diethylene glycol, pentaerythritol, 50 ethanol, butanol and octadecanol) or polyvalent alcohols; silicones such as dimethyl polysiloxane; and pyrogen-free distilled water.

The dosage of the pharmaceutical composition of the present invention varies depending on age, body weight, severity of the disease of the patient and the administration route. However, in general, the quantity of the compound of formula (I), (II), (III) and/or (IV) to be administered ranges from 0.1 to 500 mg, preferably 55 from 0.2 to 100 mg per day per kg of body weight for adult.

Pharmaceutical test

(1) In vitro test for suppressing effect of macrophage-foaming reaction using mouse abdominal cavity macrophage

5

A 15-week old ICR female mouse (Japan SLC) was amputated at its neck and exsanguinated. Then, Hanks buffer (Nissui Pharmaceutical Co., Ltd.) was injected intraperitoneally. After massaging the abdominal part, the buffer was recovered rapidly and centrifuged at 1,000 rpm for 5 minutes to collect the abdominal cavity macrophage. Then, the collected abdominal cavity macrophage was suspended in GIT medium
10 (Wako Pure Chemical Industry) and inoculated on a 24-well microplate. After culturing the macrophage for 2 hours at 37 °C in 5 % CO₂, the medium was changed into Dulbecco modified Eagle's MEM medium (Nissui Pharmaceutical Co., Ltd.). After further culturing the macrophage for 16 hours at 37 °C in 5 % CO₂, the following substances were added in order:

① Test compounds: solutions in DMSO (Wako Pure Chemical Industry)

15 1 ml of the solutions were prepared, optionally diluted and the diluted solutions were added to individual wells (500 μ l) in the amount of 5 μ l.

② Liposome

PC/PS/DCP/CHOL. = 50/50/10/75 (nmol)

PC : phosphatidylcholine (Funakoshi)

20 PS : phosphatidylserine (Funakoshi)

DCP : dicetylphosphate (Funakoshi)

CHOL. : cholesterol (Sigma)

③ ³H-Oleic acid (Amersham Japan)

Then, after still further culturing the macrophage for 16 hours at 37 °C in 5 % CO₂, the lipid fraction
25 was extracted with chloroform and methanol. The extracted lipid fraction was subjected to TLC (hexane:ether:acetic acid = 70:30:1), the separated bands of CE (cholesteryl ester) and TG (triglyceride) were borne off from the TLC plate and then the radioactivities thereof were measured using a liquid scintillation counter (PACKARD BH-22). Yields of cholesteryl ester were calculated by comparing with a control. The results are shown in Table 1.

30

35

40

45

50

55

Table 1

	Compound No.	Dosage	Yield of CE (%)	Yield of TG (%)
5				
10	(3)	5 μ M	69	89
	(5)	5 μ M	67	89
	(6)	5 μ M	8.0	61
15	(7)	5 μ M	61	91
	(8)	5 μ M	42	106
	(10)	5 μ M	69	129
20	(12)	5 μ M	52	102
	(20)	5 μ M	49	62
25	(21)	5 μ M	64	93
	(23)	5 μ M	56	119
	(27)	5 μ M	51	78
30	(28)	5 μ M	53	164
	(30)	5 μ M	51	91
	(34)	5 μ M	50	108
35	(42)	5 μ M	61	96
	(43)	5 μ M	45	98
40	(47)	5 μ M	55	98
	(52)	5 μ M	38	101
	(53)	5 μ M	56	92
45	(54)	5 μ M	25	95
	(56)	5 μ M	51	102
	(58)	5 μ M	45	98
50	(60)	5 μ M	48	96

55

	(61)	5 μ M	52	103
	(62)	5 μ M	61	98
5	(63)	5 μ M	42	96
	(65)	5 μ M	38	101
10	(66)	5 μ M	54	108
	(67)	5 μ M	42	92
	(68)	5 μ M	53	86
15	(73)	5 μ M	48	90
	(74)	5 μ M	65	108

It is clear from Table 1 that these compounds do not lower the yield of TG so far, that is, these compounds are low toxic and capable of markedly suppressing the yield of CE. Namely, these compounds markedly suppress the macrophage-foaming reaction without being highly toxic to the macrophage.

(2) Blood lipid lowering effect in rabbit fed high-cholesterol feed

(i) New Zealand White female rabbits having body weight of about 2 kg were fed feed having high cholesterol content (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast, containing 0.5 % of cholesterol and 0.5 % of olive oil) for 7 days to produce hypercholesterolemia.

Subsequently, one group consisting of 3 rabbits (treatment group) was fed the same feed in the same amount, except that the feed further contained test compound (8) in the amount of 10 0mg/kg/day/rabbit, for 7 successive days. On the other hand, as a control, another group consisting of 3 rabbits was fed the same feed in the same amount without any test compound.

A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by Iatron Laboratories Inc.

The amount of blood total cholesterol of the treatment group fell by 25 % in comparison with the control group (3 rabbits).

Thus, it is clear that test compound (8) has an excellent lowering effect of the blood cholesterol.

(ii) New Zealand White female rabbits having body weight of about 2 kg were fed feed having high cholesterol content (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast, containing 0.5 % of cholesterol and 0.5 % of olive oil) for 7 days to produce hypercholesterolemia.

Subsequently, one group consisting of 3 rabbits (treatment group) was fed the same feed in the same amount, except that the feed further contained test compound (53) in the amount of 1 00mg/kg/day/rabbit, for 7 successive days. On the other hand, as a control, another group consisting of 3 rabbits was fed the same feed in the same amount without any test compound.

A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by Iatron Laboratories Inc.

The amount of blood total cholesterol of the treatment group fell by 40 % in comparison with the control group (3 rabbits).

In the same manner, Probucol, a conventional drug, was successively administered in the amount of 100mg/kg/day for 7 days. In this case, the amount of blood total cholesterol of the treatment group fell by 15 to 20 % in comparison with the control group.

Thus, it is clear that test compound (53) has an excellent blood cholesterol lowering effect in comparison with the conventional drug.

(3) Blood lipid lowering effect in rabbit fed normal feed

(i) New Zealand White female rabbits having body weight of about 2 kg were fed normal feed (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast) for 7 days.

Subsequently, one group consisting of 3 rabbits (treatment group) was fed the normal feed in the same amount, except that the feed further contained test compound (2) in the amount of 10 0mg/kg/day/rabbit, for 7 successive days. As a control, another group consisting of 3 rabbits was fed the normal feed in the same amount without any test compound.

A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by Iatron Laboratories Inc.

The amount of blood total cholesterol of the treatment group fell by 20 % in comparison with the control group (3 rabbits).

Thus, it is clear that test compound (2) has an excellent blood cholesterol lowering effect not only on rabbits fed high-cholesterol feed but also on rabbits fed normal feed.

(ii) New Zealand White female rabbits having body weight of about 2 kg were fed normal feed (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast) for 7 days.

Subsequently, one group consisting of 3 rabbits (treatment group) was fed with the normal feed in the same amount, except that the feed further contained test compound (53) in the amount of 100mg/kg/day/rabbit, for 7 successive days. As a control, another group consisting of 3 rabbits was fed the normal feed in the same amount without any test compound.

A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by Iatron Laboratories Inc.

The amount of blood total cholesterol of the treatment group fell by 20 % in comparison with the control group (3 rabbits).

Thus, it is clear that test compound (53) has an excellent blood cholesterol lowering effect not only on rabbits fed high-cholesterol feed but also on rabbits fed normal feed.

(4) Arteriosclerosis focus formation-regressing effect in rabbit fed feed having high cholesterol content

New Zealand White female rabbits having body weight of about 2 kg were fed feed having high cholesterol content (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast, containing 0.5 % of cholesterol and 0.5 % of olive oil) for 7 days to produce hypercholesterolemia.

Subsequently, one group consisting of 3 rabbits (treatment group) was fed the same feed in the same amount, except that the feed further contained test compound (53) in the amount of 1 00mg/kg/day/rabbit, for 20 successive days. On the other hand, as a control, another group consisting of 3 rabbits was fed the same feed in the same amount without any test compound.

After 20 weeks from the administration of the test compound, the aortas and arch part thereof were removed from each rabbit and the blood vessels were opened. Comparing the treatment group with the control group, it was observed that the arteriosclerosis focus formation was suppressed effectively in the treatment group. It was also observed that the test compound suppressed the cholesterol deposition to the eye ball and fatty liver formation.

Namely, test compound (53) not only lowers the blood cholesterol value but also suppresses arteriosclerosis focus formation. In addition, test compound (53) has effect of suppressing fatty liver formation and cholesterol deposition to the eye ball.

(5) Acute toxicity test

Compounds (2) and (53) each was suspended in 0.5 % Tween 80 solution. Six 8-week old ddY mice were orally administered the suspensions respectively and were observed on acute toxicity. As a result, the LD50 value of the compounds of the present invention were found to be not less than 1000 mg/kg. This value indicates that the compounds of the present invention is low in toxicity.

EP 0 583 665 A2

Examples

Example 1 Tablet

5 Preparation of tablet containing 25 mg of compound (8)

10	① compound (8)	10 g
	② corn starch	40 g
	③ crystalline cellulose	45 g
	④ calcium carboxymethyl cellulose	4 g
	⑤ light silicic acid anhydride	500 mg
	⑥ magnesium stearate	500 mg
15		Total 100 g

① to ⑥ were homogeneously mixed and the resulting mixture was compression molded with a tableting machine to obtain tablets having weight of 250 mg. Each of these tablets contained 25 mg of compound (8). An adult may take 5 to 30 tablets over the course of one day.

20 Example 2 Tablet

Preparation of tablet containing 25 mg of compound (53)

25	① compound (53)	10 g
	② corn starch	40 g
	③ crystalline cellulose	45 g
	④ calcium carboxymethyl cellulose	4 g
	⑤ light silicic acid anhydride	500 mg
30	⑥ magnesium stearate	500 mg
		Total 100 g

① to ⑥ were homogeneously mixed and the resulting mixture was compression molded with a tableting machine to obtain tablets having weight of 250 mg. Each of these tablets contained 25 mg of compound (53). An adult may take 5 to 30 tablets over the course of one day.

Example 3 Capsule

40 Preparation of capsule containing 40 mg of compound (8)

45	① compound (8)	20 g
	③ corn starch	79.5 g
	③ light silicic acid anhydride	500 mg
		Total 100 g

① to ③ were homogeneously mixed and the resulting mixture was encapsulated in the amount of 200 mg per capsule. Each of thus-obtained capsules contained 40 mg of compound (8). An adult may take 1 to 20 capsules over the course of one day.

Example 4 Capsule

Preparation of capsule containing 40 mg of compound (53)

① compound (53)	20 g
② corn starch	79.5 g
③ light silicic acid anhydride	500 mg
	Total 100 g

① to ③ were homogeneously mixed and the resulting mixture was encapsulated in the amount of 200 mg per capsule. Each of thus-obtained capsules contained 40 mg of compound (53). An adult may take 1 to 20 capsules over the course of one day.

Example 5 Granule

Preparation of granule containing 100 mg of compound (8) per 1 g

① compound (8)	10 g
② corn starch	40 g
③ 10% hydroxypropyl cellulose solution in ethanol	50 g
	Total 100 g

① to ③ were homogeneously mixed. After kneading, the mixture was granulated with a granulating machine and dried to obtain granules. These capsules contained 100 mg of compound (8) per 1 g. An adult may take 1 to 8 g over the course of one day.

Example 6 Granule





Preparation of granule containing 100 mg of compound (53) per 1g

① compound (53)	10 g
② crystalline cellulose	40 g
③ 10% hydroxypropyl cellulose solution in ethanol	50 g
	Total 100 g

① to ③ were homogeneously mixed. After kneading, the mixture was granulated with a granulating machine and dried to obtain granules. These capsules contained 100 mg of compound (53) per 1 g. An adult may take 1 to 8 g over the course of one day.

Claims

1. A pharmaceutical composition comprising a compound of the following formula (I), (II) or (III), or a pharmaceutically-acceptable salt thereof, or a compound of the following formula (IV) as an active ingredient together with a pharmaceutically-acceptable carrier or diluent:



45 wherein

R₁ represents a hydrogen atom, an alkyl, an aryl, a mercapto, an alkylthio, an alkenylthio, an arylthio or a heterocyclo group;

R₂ represents a hydrogen atom or an alkyl group, provided that the alkyl group is not substituted by a hydroxyl group;

50 R₃ and R₄ each independently represents a hydrogen atom, a halogen atom, a nitro group, R₅O-, R₅CONH-, R₅NHCO-, (R₅)₂NCO-, R₅SO₂NH-, R₅NHSO₂-, R₅OCO-, R₅COO- or R₅NHCONH- where R₅ represents an alkyl or an aryl group;


R₆ represents a divalent group;

55 R₇, R₈, R₉ and R₁₀ each independently represents an alkyl, a cycloalkyl group, -(C(CH₃)₂)_k-(CH₂)_m-COOR₁₄ or -(C(CH₃)₂)_k-(CH₂)_m-CON(R₁₄)₂ where k represents 0 or 1, m represents an integer of 0 to 4 and R₁₄ represents a lower alkyl group;

R₁₁ and R₁₂ each independently represents a hydrogen atom, and alkyl, an aryl or an aralkyl group; and

R_{13} represents a hydrogen atom, a lower alkyl, an aralkyl, an acyl, an alkyl- or arylsulfonyl group, or $-(CH_2)_nCOOR_{15}$ where n represents an integer of 0 to 2 and R_{15} represents a lower alkyl group.

2. The pharmaceutical composition according to claim 1, wherein the active ingredient is the compound of the formula (I).
3. The pharmaceutical composition according to claim 2, wherein the compound of the formula (I) is represented by the following formula (V);



wherein

- R_1 represents a hydrogen atom, an alkyl, a mercapto or an alkylthio group; and
 R_3 represents a hydrogen atom, a halogen atom, a nitro group, R_5O , R_5CONH- , R_5NHCO- , R_5NHSO_2- or R_5SO_2NH- where R_5 represents an alkyl group.
4. The pharmaceutical composition according to claim 3, wherein
 R_1 represents a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, a mercapto group or an alkylthio group having 1 to 18 carbon atoms; and
 R_5 represents an alkyl group having 1 to 20 carbon atoms.
5. The pharmaceutical composition according to claim 3, wherein
 R_1 represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a mercapto group or an alkylthio group having 1 to 8 carbon atoms; and
 R_5 represents an alkyl group having 4 to 18 carbon atoms.
6. The pharmaceutical composition according to claim 1, wherein the active ingredient is the compound of the formula (IV).
7. The pharmaceutical composition according to claim 6, wherein
 R_7 , R_8 , R_9 and R_{10} each independently represents an alkyl group having 1 to 12 carbon atoms, cyclopentyl, cyclohexyl, cycloheptyl group, $-(C(CH_3)_2)_k-(CH_2)_mCOOR_{14}$ or $-(C(CH_3)_2)_k-(CH_2)_mCON-(R_{14})_2$ where k represents 0 or 1, m represents an integer of 0 to 4 and R_{14} represents a lower alkyl group;
 R_{11} and R_{12} each independently represents a hydrogen atom, an alkyl group having 1 to 13 carbon atoms, phenyl, tolyl, xylyl, naphthyl, benzyl or phenethyl group; and
 R_{13} represents a hydrogen atom, a lower alkyl, benzyl, phenethyl group, an aliphatic acyl group having 2 to 6 carbon atoms, benzoyl group, an alkylsulfonyl group having 2 to 4 carbon atoms, benzenesulfonyl, p-toluenesulfonyl group, or $-(CH_2)_nCOOR_{15}$ where n represents an integer of 0 or 1 and R_{15} represents a lower alkyl group.
8. The pharmaceutical composition according to claim 6, wherein
 R_7 , R_8 , R_9 and R_{10} each independently represents an alkyl group having 1 to 4 carbon atoms or cycloalkyl group substituted by methyl group;
 R_{11} and R_{12} each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; and
 R_{13} represents a hydrogen atom.
9. The pharmaceutical composition according to claim 1, wherein the composition is for treating hyperlipidemia and arteriosclerosis.

10. A use of compound of the formula (I), (II) or (III), or a pharmaceutically-acceptable salt thereof, or a compound of the formula (IV) as defined in claim 1, in preparation of a pharmaceutical composition for treating antihyperlipidemia and antiarteriosclerosis in mammals, preferably man.

5

10

15

20

25

30

35

40

45

50

55



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 583 665 A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **93112181.8**

(22) Date of filing: **29.07.93**

(51) Int. Cl. 5: **A61K 31/05, A61K 31/165,
A61K 31/215, A61K 31/235,
A61K 31/415, A61K 31/505,
A61K 31/535**

(30) Priority: **30.07.92 JP 204122/92**
02.09.92 JP 234767/92

(43) Date of publication of application:
23.02.94 Bulletin 94/08

(84) Designated Contracting States:
CH DE FR GB IT LI

(88) Date of deferred publication of the search report:
18.05.94 Bulletin 94/20

(71) Applicant: **FUJI PHOTO FILM CO., LTD.**
No. 210, Nakanuma
Minami-Ashigara-shi
Kanagawa-ken(JP)

(72) Inventor: **Aikawa, Kazuhiro, c/o Fuji Photo**
Film Co., Ltd.
No. 210, Nakanuma
Minami-Ashigara-shi, Kanagawa-ken(JP)
Inventor: **Aoki, Kozo, c/o Fuji Photo Film Co.,**
Ltd.
No. 210, Nakanuma
Minami-Ashigara-shi, Kanagawa-ken(JP)

(74) Representative: **Hansen, Bernd, Dr.**
Dipl.-Chem. et al
Hoffmann, Eitle & Partner,
Patentanwälte,
Arabellastrasse 4
D-81925 München (DE)

(54) **Pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis.**

(57) Disclosed are an antihyperlipidemia or antiarteriosclerosis agent comprising a certain benzimidazole or 2,2'-methylenebisphenol derivative such as 5-dodecanoylamino-2-mercaptobenzimidazole or 2,2'-isobutylidenebis(4,6-dimethylphenol).

EP 0 583 665 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 11 2181

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	AMERICAN JOURNAL OF PATHOLOGY vol. 139, no. 1, 1 July 1991, pages 217 - 229 MCGUIRE E.J., ET AL., 'Peroxisome induction potential and lipid-regulating activity in rats' * see page 222, compound "L"; Tables 2 and 3, p. 217-218 (Introduction) * ---	1,2,9,10	A 61 K 31/05 A 61 K 31/165 A 61 K 31/215 A 61 K 31/235 A 61 K 31/415 A 61 K 31/505 A 61 K 31/535
X	EP-A-0 167 943 (BEECHAM) 15 January 1986 * see claims 1-11,13; Examples 7a - 29a * ---	1-5	
X	US-A-3 658 822 (FAURAN ET AL.) 25 April 1972 * see column 1, lines 15-34 * ---	1-5	
X	EP-A-0 074 341 (AKTIEBOLAGET) 16 March 1983 * see claims 1-20 * ---	1-5	
X	S. BUDAVARI, ED. 'The Merck Index' 1989, MERCK & CO., RAHWAY USA * see page 1156, No 7245; pages 1462-3, No 9217 * ---	1,2	TECHNICAL FIELDS SEARCHED (Int. Cl.5) A 61 K
A	* see pages 168-9, Nos 1091,1092 * ---	1-5	
X	EP-A-0 352 864 (ZAMBON) 31 January 1990 * see page 2 lines 29-33; claim 3 * --- -/-	1-5,9,10	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 15-11-1993	Examiner INSERT B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet -B-

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims: mentioned in item 1.



European Patent
Office

EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 93 11 2181

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	INT. J. OBES. vol. 11, 1987, pages 619 - 629 F.M. WHITTINGTON ET AL. 'Effect of sodium 2-n-pentadecyl-benzimidazole-5-carboxylate (M & B 35347B) an inhibitor of acetyl-CoA-carboxylase, on lipogenesis and fat deposition in obese hyperglycaemic (ob/ob) and lean mice' * see the abstract *	1-5, 9, 10
		CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
		TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The present search report has been drawn up for all claims		
Place of search MUNICH		Date of completion of the search 15-11-1993
CATEGORY OF CITED DOCUMENTS		Examiner ISERT B
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>		



European Patent
Office

93 112 181.8

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

Annex Supplemental sheet B: EP 93112181.8

- 1.) Pharmaceutical compositions comprising a compound of the formulas I-III
(see claims 1 in part, 2-5, 9 in part, 10 in part)
- 2.) Pharmaceutical compositions comprising a compound of the formula IV (see claims 1 in part, 6-8, 9 in part, 10 in part)